These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

336 related items for PubMed ID: 3901645

  • 21. Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production.
    Butterfield JH, Weiler CR.
    Int Arch Allergy Immunol; 2008; 147(4):338-43. PubMed ID: 18622141
    [Abstract] [Full Text] [Related]

  • 22. [Benign systemic mastocytosis: report of 2 cases].
    Velloso ED, Beitler B, Chamone DA.
    Rev Hosp Clin Fac Med Sao Paulo; 1991; 46(2):94-8. PubMed ID: 1843375
    [Abstract] [Full Text] [Related]

  • 23. An immunohistochemical study of the bone marrow lesions of systemic mastocytosis: expression of stem cell factor by lesional mast cells.
    Akin C, Jaffe ES, Raffeld M, Kirshenbaum AS, Daley T, Noel P, Metcalfe DD.
    Am J Clin Pathol; 2002 Aug; 118(2):242-7. PubMed ID: 12162685
    [Abstract] [Full Text] [Related]

  • 24. Urinary 11β-PGF2α and N-methyl histamine correlate with bone marrow biopsy findings in mast cell disorders.
    Divekar R, Butterfield J.
    Allergy; 2015 Oct; 70(10):1230-8. PubMed ID: 26095439
    [Abstract] [Full Text] [Related]

  • 25. Tryptase and histamine metabolites as diagnostic indicators of indolent systemic mastocytosis without skin lesions.
    van Doormaal JJ, van der Veer E, van Voorst Vader PC, Kluin PM, Mulder AB, van der Heide S, Arends S, Kluin-Nelemans JC, Oude Elberink JN, de Monchy JG.
    Allergy; 2012 May; 67(5):683-90. PubMed ID: 22435702
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Current approaches to the diagnosis and treatment of systemic mastocytosis.
    Bains SN, Hsieh FH.
    Ann Allergy Asthma Immunol; 2010 Jan; 104(1):1-10; quiz 10-2, 41. PubMed ID: 20143640
    [Abstract] [Full Text] [Related]

  • 33. [Acute myelomonocytic leukemia with mastocytosis in bone marrow].
    Natori H, Nakamura E, Tanaka K, Naito K, Egami K, Honda J, Osabe S, Imamura Y, Natori K, Yasuda K.
    Rinsho Ketsueki; 1990 Feb; 31(2):239-44. PubMed ID: 2329687
    [Abstract] [Full Text] [Related]

  • 34. Hematopathology of the bone marrow in pediatric cutaneous mastocytosis. A study of 17 patients.
    Kettelhut BV, Parker RI, Travis WD, Metcalfe DD.
    Am J Clin Pathol; 1989 May; 91(5):558-62. PubMed ID: 2470248
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Diagnosis of mastocytosis subsets using a morphometric point counting technique.
    Kasper CS, Freeman RG, Tharp MD.
    Arch Dermatol; 1987 Aug; 123(8):1017-21. PubMed ID: 2443079
    [Abstract] [Full Text] [Related]

  • 37. Serum tryptase and SCORMA (SCORing MAstocytosis) Index as disease severity parameters in childhood and adult cutaneous mastocytosis.
    Heide R, van Doorn K, Mulder PG, van Toorenenbergen AW, Beishuizen A, de Groot H, Tank B, Oranje AP.
    Clin Exp Dermatol; 2009 Jun; 34(4):462-8. PubMed ID: 19077102
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. The spectrum of mastocytosis.
    Tharp MD.
    Am J Med Sci; 1985 Mar; 289(3):119-32. PubMed ID: 2579553
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.